Moflox

Community-acquired pneumonia caused by Strep pneumoniae, H. influenzae, Mycoplasma pneumoniae, Chlamydia pneumoniae or Moraxella catarrhalis. Complicated skin & skin structure infections caused by methicillin-susceptible Staph aureus, E. coli, Klebsiella pneumoniae or Enterobacter cloacae.

IV Adult 400 mg once daily infused over 60 min. Community-acquired pneumonia Total treatment duration for sequential administration (IV followed by oral): 7-14 days. Complicated skin & skin structure infection Total treatment duration for sequential administration (IV followed by oral): 7-21 days.

Hypersensitivity to moxifloxacin or other quinolones. Patients w/ history of tendon disease/disorder-related to quinolone treatment. Patients w/ congenital or documented acquired QT prolongation; electrolyte disturbances particularly in uncorrected hypokalaemia; clinically relevant bradycardia or heart failure w/ reduced left-ventricular ejection fraction; history of symptomatic arrhythmias. Do not use concurrently w/ other QT interval-prolonging drugs. Patients w/ increased transaminases >5-fold ULN. Impaired liver function (Child-Pugh C). Pregnancy & lactation. Patients <18 yr.

Quinolones

J01MA14 - moxifloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.